We show that by BMD, TMP/SMX has high rates of susceptibility to β-hemolytic Streptococcus demonstrating its ability for monotherapy against both S. aureus and β-hemolytic Streptococcus spp. 💊https://t.co/1U8nAoHQcf
🚨Interested/know someone interested in pursuing a PGY2 ID pharm residency?🚨@BMCPharmRes will be hosting a virtual open house next week (details below). Come meet @EKBPharmD, @_MarissaRees and our other awesome ID preceptors to learn more about the program! 🦠🦠
Join @Pharma_Seeds, @PharmD_Kev, @_MarissaRees, and Dr. Blackman in their discussion of #voriconazole TDM for Invasive Aspergillosis in one of the latest @SIDPharm Journal Club series (https://t.co/gTtPZxITyq), worth 1.5h of ACPE/BCIDP Credit! 🍄💊 #IDTwitter#TwitteRx
Boston Medical Center has a few programs entering Phase II
Be sure to check us out if your interested in:
- Oncology (carT, gene therapy, Outpatient mng)
-IM (TOC, unique pop, SUD)
-1/2 HSPAL +MS (system opportunity in compact & adaptable sys)
https://t.co/620OC4Sklq
My co-resident Maggie and I are proud to present our PGY1 research projects this week at the IDWeek 2022 conference! @AHNRxResidency @marge_at_large_#IDWeek
Making a lecture on endocarditis and you already know what direction we’re headed.
@DEZ_EM_Pharm showed me this years ago and it lives rent free in my head
#FeatureFriday 🔦 Aoife Iaria is a PGY2 in SOT at the University of Illinois at Chicago! Check out her full blog and find the link to her podcast about the “Evaluation of Cytomegalovirus Blips in high risk kidney/kidney-pancreas transplant recipients” on the IMTR listserv! ✨
IN PRESS: A significantly lower incidence of AKI in patients receiving vancomycin dosed by AUC based goal troughs was observed compared to traditional trough dosing @_MarissaRees#TwitteRx#pharmacists
https://t.co/8THkiLtzv5
@robert_c1234@dnbrems@DustinRCarr@CessnaPharmD @carleyb1016 We observed a higher incidence of AKI with the 15-20 range. In the AUC based dosing group, the average trough range was about 11-17.
Check out our ID resident's @_MarissaRees awesome work demonstrating the benefits of an individualized AUC-based trough range for patients being discharged on vancomycin OPAT.
https://t.co/KJboo8s9Y9
@DustinRCarr@CessnaPharmD @carleyb1016
Check out our ID resident @_marissarees poster on the occurrence of vancomycin associated AKI as an outpatient utilizing an individualized goal trough range derived from an inpatient AUC compared to traditional trough dosing.
https://t.co/sR8LEUUwJd
#IDWeek2021@DustinRCarr
Very excited to be presenting my research on the incidence of AKI with AUC dosing of vancomycin in the outpatient setting at IDWeek! #IDWeek2021 https://t.co/Pf8a22plIb